Management of Chronic HBV-HDV Patients Chronic HBV-HDV Infection: A Review on New Management Options

Overview

Journal United European Gastroenterol J

Publisher Wiley

Specialty Gastroenterology

Date 2023 Dec 2

PMID 38041549

Authors

Maria Buti

Alexia Gonzalez

Mar Riveiro-Barciela

Marc Bourliere

Affiliations

Soon will be listed here.

Abstract

Hepatitis D virus was first described by Mario Rizzeto in 1977, and it is considered chronic viral hepatitis with the poorest prognosis. Despite its discovery almost 50 years ago, progress in its diagnosis and treatment has been scarce until recent years. The approval of bulevirtide has shed some light for patients with Chronic Hepatitis D, although important gaps regarding its use in therapy as well as about the epidemiology and diagnosis of the disease need to be addressed.

Citing Articles

Liver transplantation for HBV-related liver disease: Impact of prophylaxis for HBV on HCC recurrence.

Burra P, Battistella S, Turco L, Morelli M, Frassanito G, De Maria N JHEP Rep. 2025; 7(3):101278.

PMID: 40041120 PMC: 11876922. DOI: 10.1016/j.jhepr.2024.101278.

Results of Response-Guided Therapy with Pegylated Interferon Alpha 2a in Chronic Hepatitis B and D.

Gherlan G, Lazar S, Culinescu A, Smadu D, Vatafu A, Popescu C Trop Med Infect Dis. 2024; 9(4).

PMID: 38668534 PMC: 11054492. DOI: 10.3390/tropicalmed9040073.

Management of chronic HBV-HDV patients chronic HBV-HDV infection: A review on new management options.

Buti M, Gonzalez A, Riveiro-Barciela M, Bourliere M United European Gastroenterol J. 2023; 12(2):210-218.

PMID: 38041549 PMC: 10954430. DOI: 10.1002/ueg2.12494.

Evolution in diagnosis and management of chronic liver diseases.

Moreno C, Qi X United European Gastroenterol J. 2023; 11(10):945-947.

PMID: 38015649 PMC: 10720681. DOI: 10.1002/ueg2.12502.

References

Kamal H, Westman G, Falconer K, Duberg A, Weiland O, Haverinen S . Long-Term Study of Hepatitis Delta Virus Infection at Secondary Care Centers: The Impact of Viremia on Liver-Related Outcomes. Hepatology. 2020; 72(4):1177-1190. DOI: 10.1002/hep.31214. View

Yurdaydin C, Keskin O, Kalkan C, Karakaya F, Caliskan A, Kabacam G . Interferon Treatment Duration in Patients With Chronic Delta Hepatitis and its Effect on the Natural Course of the Disease. J Infect Dis. 2018; 217(8):1184-1192. DOI: 10.1093/infdis/jix656. View

Dietz-Fricke C, Tacke F, Zollner C, Demir M, Schmidt H, Schramm C . Treating hepatitis D with bulevirtide - Real-world experience from 114 patients. JHEP Rep. 2023; 5(4):100686. PMC: 10071092. DOI: 10.1016/j.jhepr.2023.100686. View

Jachs M, Schwarz C, Panzer M, Binter T, Aberle S, Hartl L . Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-results of a "real world" study. Aliment Pharmacol Ther. 2022; 56(1):144-154. PMC: 9321570. DOI: 10.1111/apt.16945. View

Buti M, Gonzalez A, Riveiro-Barciela M, Bourliere M . Management of chronic HBV-HDV patients chronic HBV-HDV infection: A review on new management options. United European Gastroenterol J. 2023; 12(2):210-218. PMC: 10954430. DOI: 10.1002/ueg2.12494. View

Jachs M, Panzer M, Hartl L, Schwarz M, Balcar L, Camp J . Long-term follow-up of patients discontinuing bulevirtide treatment upon long-term HDV-RNA suppression. JHEP Rep. 2023; 5(8):100751. PMC: 10285645. DOI: 10.1016/j.jhepr.2023.100751. View

Heidrich B, Yurdaydin C, Kabacam G, Ratsch B, Zachou K, Bremer B . Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology. 2014; 60(1):87-97. DOI: 10.1002/hep.27102. View

Romeo R, Del Ninno E, Rumi M, Russo A, Sangiovanni A, De Franchis R . A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology. 2009; 136(5):1629-38. DOI: 10.1053/j.gastro.2009.01.052. View

Wedemeyer H, Schoneweis K, Bogomolov P, Blank A, Voronkova N, Stepanova T . Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial. Lancet Infect Dis. 2022; 23(1):117-129. DOI: 10.1016/S1473-3099(22)00318-8. View

10.

Rizzetto M, Canese M, Arico S, Crivelli O, Trepo C, Bonino F . Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut. 1977; 18(12):997-1003. PMC: 1411847. DOI: 10.1136/gut.18.12.997. View

11.

. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017; 67(2):370-398. DOI: 10.1016/j.jhep.2017.03.021. View

12.

Stockdale A, Chaponda M, Beloukas A, Phillips R, Matthews P, Papadimitropoulos A . Prevalence of hepatitis D virus infection in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Glob Health. 2017; 5(10):e992-e1003. PMC: 5599428. DOI: 10.1016/S2214-109X(17)30298-X. View

13.

Yurdaydin C, Abbas Z, Buti M, Cornberg M, Esteban R, Etzion O . Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. J Hepatol. 2019; 70(5):1008-1015. DOI: 10.1016/j.jhep.2018.12.022. View

14.

Razavi H, Buti M, Terrault N, Zeuzem S, Yurdaydin C, Tanaka J . Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries. J Hepatol. 2023; 79(2):576-580. DOI: 10.1016/j.jhep.2023.02.041. View

15.

Sarin S, Kumar M, Lau G, Abbas Z, Chan H, Chen C . Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2015; 10(1):1-98. PMC: 4722087. DOI: 10.1007/s12072-015-9675-4. View

16.

Anolli M, Degasperi E, Allweiss L, Sangiovanni A, Maggioni M, Scholtes C . A 3-Year Course Of Bulevirtide Monotherapy May Cure Hdv Infection In Cirrhotics. J Hepatol. 2023; . DOI: 10.1016/j.jhep.2022.12.023. View

17.

Degasperi E, Anolli M, Uceda Renteria S, Sambarino D, Borghi M, Perbellini R . Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension. J Hepatol. 2022; 77(6):1525-1531. DOI: 10.1016/j.jhep.2022.07.016. View

18.

Wedemeyer H, Yurdaydin C, Hardtke S, Caruntu F, Curescu M, Yalcin K . Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. Lancet Infect Dis. 2019; 19(3):275-286. DOI: 10.1016/S1473-3099(18)30663-7. View

19.

Chen H, Shen D, Ji D, Han P, Zhang W, Ma J . Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. Gut. 2018; 68(3):512-521. DOI: 10.1136/gutjnl-2018-316601. View

20.

Caviglia G, Martini S, Ciancio A, Niro G, Olivero A, Fontana R . The hepatitis D virus in Italy. A vanishing infection, not yet a vanished disease. J Adv Res. 2021; 33:183-187. PMC: 8463926. DOI: 10.1016/j.jare.2021.02.009. View